TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Blog > Your guide to claiming temporary exemption from TGO91/92 compliance

Your guide to claiming temporary exemption from TGO91/92 compliance

Author: Nicole Tan

As described in the article, Addendum to TGA Deadlines: Medicine Labelling Compliance and COVID-19, 31 August 2020 marked the end of the medicines packaging reform transition. The intent of the reform was to make Australian medicine labels clearer and more informative for patients and consumers. As such, from 1 September 2020, all medicines released for supply must now comply with the relevant TGA labelling standard. Unless specifically excluded in the relevant Order (TGO 91 or TGO 92), it is illegal to supply medicines that are not compliant, unless prior consent has been provided by the TGA under section 14 of the Therapeutic Goods Act 1989.

How do I claim an exemption?

A medicine sponsor can make an application for exemption to the TGA under the standard pathway, or via a temporary streamlined pathway that has been specifically designed to ease the business pressures that COVID-19 has placed on the industry, by making an allowance for delayed implementation of TGO91/92 compliant labels. To streamline this process, evaluation of product labelling is not required.

Please note the expedited pathway for section 14 consents for supply of medicines without TGO 91 compliant labels will cease on 9 October 2020.

In the addition to the above, there is also an interim process for non-prescription medicine sponsors to request consent for non-compliance with subsection 9(2) of TGO92, which requires that:

  • the medicine name be presented in an uninterrupted and continuous manner (i.e. the complete name all in one place on the label).
  • the use of trademarks, graphics or additional text must not disrupt the medicine name. This will ensure that the medicine name is clearly recognisable.

This option has been introduced to specifically address the difficulty that some sponsors have had in complying with this requirement because their brand name is iconic and includes a ‘distinguishing mark’ such as a registered trademark, a graphic image, logo, slogan or tagline, within or adjacent to the brand name.

What is the duration of consent?

Under each pathway, the sponsor will need to identify either impacted batch number(s) for the affected goods and/or nominate a period which would cover manufacture of the impacted batches. If using the latter approach, a rationale for the proposed duration of the period must be provided.

Note that all COVID-19-related consents to supply goods that do not comply with TGO92 will end on 6 March 2021, which aligns with the end of the transition period for permitted indications, a separate, but parallel reform also involving implementation of major label changes. In general, the duration of the consent from compliance with subsection 9(2) of TGO92 will be limited to 1 September 2021. A longer consent period for both exemption types may be considered under exceptional circumstances.

How much does an exemption cost?

The current cost is $490 per application. An application can include goods in multiple ARTG entries provided:

  • the goods have the same sponsor
  • the goods have the same non-compliance to the same part or parts of TGO91/92
  • the goods have the same distinguishing mark, e.g. registered trademark, a graphic image, icon or logo, a brand name, slogan or tagline (only in the case of non-compliance with subsection 9(2) of TGO92)

How long does it take for TGA to decide on my exemption request?

A target of 5 working days for COVID-related TGO91 non-compliance, and
5-10 working days for COVID-19-related TGO92 non-compliance. A statutory or target timeframe for TGA’s decision has not been specified for the other pathways. Sponsors may also request priority review of a section 14 consent to allay the severity of a medicine shortage after submitting the relevant shortage notification. Any decision to reject must be notified to the sponsor within 28 days with reasons. In granting an exemption, the Delegate may impose a condition on the consent (under section 15 of the Act) to mitigate risk in supplying the non-compliant product.

Will the decision be made public?

Yes, all approved consents are publicly available on its website. The online repository permits searches by sponsor, product name, batch number, ARTG number, date of consent and year. Any decisions to reject are not required to be published. Consents granted via two of the pathways (standard and TGO91 streamlined) are published on TGA’s website:

  • Database of consents to import, supply or export therapeutic goods that do not comply with standards
  • Database of consents for prescription medicines that do not comply with TGO 91 labelling due to COVID-19

Can I appeal the decision?

Yes, the rights of review are included in the decision letter to the sponsor. The sponsor has a right under section 60 of the Therapeutic Goods Act 1989 to seek an internal review of the TGA’s decision or the condition(s) imposed on consent within 90 days of being notified. The sponsor may also request a review by the Administrative Appeals Tribunal within 28 days starting on the day the decision was made.

Which pathway should I apply under and what are the data requirements?
This may depend on the particular circumstances of the impacted product and/or the reason for the delay in implementation. Table 1 describes the eligibility criteria for the respective pathways.

Table 1 Summary of the pathways available to sponsors of medicines which may be non-compliant with the applicable labelling orders

Contact us
Related posts
Is quality documentation an asset or a burden in regulatory affairs?
Is quality documentation an asset or a burden in regulatory affairs?
6th April 2022
Navigating the impact of the IVDR on marketed products
Navigating the impact of the IVDR on marketed products
24th March 2022
Minimizing risk during the transport of medicinal products
Minimizing risk during the transport of medicinal products
21st March 2022
Next Steps for EUDAMED implementation within MDR
Next Steps for EUDAMED implementation within MDR
7th March 2022
How Advanced Therapeutic Mergers & Acquisitions Impact Negotiations and Integration
How Advanced Therapeutic Mergers & Acquisitions Impact Negotiations and Integration
26th February 2022
Planning for Post-Emergency Use Authorization (EUA) for Medical Devices and IVDs
Planning for Post-Emergency Use Authorization (EUA) for Medical Devices and IVDs
24th February 2022
Recent Blogs
  • Is quality documentation an asset or a burden in regulatory affairs?
    6th April 2022
  • Navigating the impact of the IVDR on marketed products
    24th March 2022
  • Minimizing risk during the transport of medicinal products
    21st March 2022
  • Next Steps for EUDAMED implementation within MDR
    7th March 2022
  • How Advanced Therapeutic Mergers & Acquisitions Impact Negotiations and Integration
    26th February 2022
  • Planning for Post-Emergency Use Authorization (EUA) for Medical Devices and IVDs
    24th February 2022
Recent News
  • Addressing Limitations of Sterility Testing
    9th May 2022
  • Are virtual audits sustainable post-pandemic?
    6th May 2022
  • Orphan Drug Designation: Securing the Significant Benefits
    28th March 2022
  • PharmaLex expands pricing & reimbursement and health economics platform with EBMA Consulting merger
    9th March 2022
  • PharmaLex extends reach to Japan, East Asia and Southeast Asia with Ascent Development Services merger
    8th February 2022
  • Virtual Audits: To be, or not to be, that is the question
    26th January 2022
Upcoming Events

September 28 - May 29th, 2022

NLS DAYS 2022

Visit us at booth X51

Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
18 May

Listen to our #podcast:
➡  Navigating a complex regulatory environment with medical device software

#SaMD #Medicaldevices #regulatoryaffairs

https://lnkd.in/eqKbz89J

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • I just wanted to relay our sincere thanks to you and the team for two really excellent days training. It was well organized and structured to cover regulatory expectations, GMP principle and routine work challenges of industry. The presenters and moderator were highly skilled in this area to accommodate any queries raised during the training session and were well able to keep the team engaged even in remote/virtual training session. The design of training slides was impressive and the use of technology to make virtual training was remarkable.

    Lorraine Henry
    Compliance Lead, Qualified Person, Amneal Ireland Limited
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for